INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

Cancer Statistics, 2008

Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184

Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer

Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340

Mechanisms and functional significance of tumour-induced dendritic-cell defects

Gabrilovich, D. I. (2004) · Nature reviews. Immunology · doi:10.1038/nri1498 · Cited by 1,022

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., CLARK, P. I., Palmer, M., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 636

Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells

Becker, T. C., Noel, R. J., Coats, W. S., Gómèz‐Foix, A. M., Alam, T., Gerard, R. D., & Newgard, C. B. (1994) · Methods in cell biology · doi:10.1016/s0091-679x(08)60603-2 · Cited by 569

All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Mirza, N. N., Fishman, M., Fricke, I., Dunn, M. W., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S. J., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 566

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538

Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells

Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538

Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells

Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527

Lung cancer immunotherapy: progress, pitfalls, and promises

Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102

Lung cancer: Biology and treatment options

Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,067

Drugging p53 in cancer: one protein, many targets

Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771

Immune parameters affecting the efficacy of chemotherapeutic regimens

Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 686

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381

Trial watch

Vacchelli, E., Vitale, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Cremer, I., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 251

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

Adams, S., Kozhaya, L., Martiniuk, F. T., Meng, T., Chiriboga, L. A., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 223

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer

Schvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J. J., Roarty, E. B., Lacerda, L., Swisher, S. G., Heymach, J. V., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.034 · Cited by 217

Therapeutic targeting of tumor suppressor genes

Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 209

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 198

Recent Advances in p53 Research and Cancer Treatment

Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 191

Application of Evolutionary Principles to Cancer Therapy

Enríquez‐Navas, P. M., Wojtkowiak, J. W., & Gatenby, R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1337 · Cited by 175

Trial watch

Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 151

Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment

Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 137

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

Pirollo, K. F., Nemunaitis, J. J., Leung, P. K., Nunan, R., Adams, J., & Chang, E. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.135 · Cited by 118

Interactions between the tumor suppressor p53 and immune responses

Menéndez, D., Shatz, M., & Resnick, M. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 115

Cancer stem cells and immunoresistance: clinical implications and solutions.

Codony‐Servat, J., & Rosell, R. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.11 · Cited by 112

Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines

Gulley, J. L., Madan, R. A., & Schlom, J. (2011) · Current Oncology · doi:10.3747/co.v18i3.783 · Cited by 100

The role of immunotherapy in small cell lung cancer

Calles, A., Aguado, G., Sandoval, C., & Alvarez, R. M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02011-9 · Cited by 102

Chemoimmunotherapy

Emens, L. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb5066 · Cited by 101

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103

SCLC–State of the Art and What Does the Future Have in Store?

Kahnert, K., Kauffmann-Guerrero, D. E., & Huber, R. M. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.014 · Cited by 76

Polymeric oncolytic adenovirus for cancer gene therapy

Choi, J.-W., Lee, Y. S., Yun, C., & Kim, S. W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.009 · Cited by 73

Dendritic Cell-Based Immunotherapy in Lung Cancer

Stevens, D., Ingels, J., Lint, S. V., Vandekerckhove, B., & Vermaelen, K. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620374 · Cited by 73

Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines

Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 72

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64

Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma

Pestana, R. C., Becnel, M., Rubin, M. L., Torman, D., Crespo, J., Phan, J., Hanna, E. Y., Bell, D., Glisson, B. S., Johnson, J. M., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104523 · Cited by 61

Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer

Hall, R. D., Gray, J. E., & Chiappori, A. (2013) · Cancer Control · doi:10.1177/107327481302000105 · Cited by 57

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

Weide, B., Eigentler, T., Pflugfelder, A., Leiter, U., Meier, F. E., Bauer, J. M., Schmidt, D., Radny, P., Pföhler, C., & Garbe, C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0957-3 · Cited by 55

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

Sweet, K. L., Hazlehurst, L., Sahakian, E., Powers, J. J., Nodzon, L., Kayali, F., Hyland, K. A., Nelson, A. M., & Pinilla-Ibarz, J. A. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.10.002 · Cited by 56

A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer

Soliman, H. H., Khambati, F. A., Han, H. S., Ismail-Khan, R. R., Bui, M. M., Sullivan, D. M., & Antonia, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24118 · Cited by 54

Novel therapies in small cell lung cancer.

Mamdani, H. M., Induru, R. R., & Jalal, S. I. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.07.20 · Cited by 52

Negatively Charged Magnetite Nanoparticle Clusters as Efficient MRI Probes for Dendritic Cell Labeling and In Vivo Tracking

Wu, C., Xu, Y., Yang, L., Wu, J., Zhu, W., Li, D., Cheng, Z., Xia, C., Guo, Y., Gong, Q., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501031 · Cited by 51

Novel Therapies for Small Cell Lung Cancer

Koczywas, M., & Amanam, I. U. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_8 · Cited by 51

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Jadus, M. R., Natividad, J., Mai, A., Ouyang, Y. Q., Lambrecht, N. W. G., Szabó, S., Ge, L., Hoa, N. T., & Dacosta-Iyer, M. G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/160724 · Cited by 49

Cancer evolution: A means by which tumors evade treatment

Zhu, X. M., Shi, L., Xu, B., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111016 · Cited by 51

New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy

Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 47

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors

Li, Y., Li, B., Li, C., & Li, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.990882 · Cited by 41

A new hope: the immunotherapy in small cell lung cancer

LI, Q., YUAN, D., Ma, C., LIU, Y., Ma, L., Lv, T., & Song, Y. (2016) · Neoplasma · doi:10.4149/302_151001n511 · Cited by 41

Role of myeloid-derived suppressor cells in metastasis

Cole, K., Pravoverov, K., & Talmadge, J. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09947-x · Cited by 38

Pharmacological Activation of p53 in Cancer Cells

Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 40

Dendritic Cells in the Pathogenesis and Treatment of Human Diseases: A Janus Bifrons?

Cools, N., Petrizzo, A., Smits, E., Buonaguro, L., Tornesello, M. L., Berneman, Z. N., & Buonaguro, L. (2011) · Immunotherapy · doi:10.2217/imt.11.110 · Cited by 36

Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention

El-Nikhely, N. A., Larzábal, L., Seeger, W., Calvo, A., & Savai, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.693478 · Cited by 35

Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success.

Lin, X., Li, W., Lai, J., Okazaki, M., Sugimoto, S., YAMAMOTO, S., Wang, X., Gelman, A. E., Kreisel, D., & Krupnick, A. S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.06.02 · Cited by 34

Radiation and Anti-Cancer Vaccines: A Winning Combination

Cadena, A. P., Cushman, T. R., Anderson, C., Barsoumian, H. B., Welsh, J. S., & Cortez, M. A. (2018) · Vaccines · doi:10.3390/vaccines6010009 · Cited by 34

Next Generation Cancer Vaccines—Make It Personal!

Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 33

Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Sayed, R. E., & Blais, N. (2021) · Current Oncology · doi:10.3390/curroncol28050347 · Cited by 31

Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents

Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 31

The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02052 · Cited by 27

Modulation of immune responses by the tumor suppressor p53

Lowe, J. M., Shatz, M., Resnick, M. A., & Menéndez, D. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.2 · Cited by 30

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer

Saito, M., Shiraishi, K., Goto, A., Suzuki, H. Y., Kohno, T., & Kono, K. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy068 · Cited by 29

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Ding, X., Cao, H., Chen, X., Jin, H., Liu, Z., Wang, G., Cai, L., Li, D., Niu, C. S., Tian, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0514-0 · Cited by 28

Role of myeloid-derived suppressor cells in tumor recurrence

Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10079-1 · Cited by 30

Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

Terazaki, Y., Yoshiyama, K., Matsueda, S., Watanabe, N., Kawahara, A., Naito, Y., Suekane, S., Komatsu, N., Ioji, T., Yamada, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02202.x · Cited by 24

Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer

Lin, Y., Lai, Q., Gou, L., Feng, J., & Yang, J. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1797050 · Cited by 25

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29

Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?

Shurin, M. R., Gregory, M., Morris, J. C., & Malyguine, A. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.526105 · Cited by 22

Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment

Abascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 23

Gene-modified dendritic cell vaccines for cancer

Abraham, R. S., & Mitchell, D. A. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.009 · Cited by 21

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Patel, S. H., Rimner, A., & Cohen, R. B. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.04 · Cited by 20

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

Maylin, Z. R., Smith, C. D., Classen, A., Asim, M., Pandha, H., & Wang, Y. Z. (2024) · Cells · doi:10.3390/cells13231999 · Cited by 21

Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer

Lum, C., & Alamgeer, M. (2019) · Cancers · doi:10.3390/cancers11101570 · Cited by 20

Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy

Tessarollo, N. G., Domingues, A. C. M., Antunes, F., da Luz, J. C. D. S., Rodrigues, O. A., Cerqueira, O. L. D., & Strauss, B. E. (2021) · Cancers · doi:10.3390/cancers13081863 · Cited by 19

Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy

Kumari, K., Singh, A., Chaudhary, A., Singh, R. K., Shanker, A., Kumar, V., & Haque, R. (2024) · Vaccines · doi:10.3390/vaccines12050498 · Cited by 20

Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro

Saito, H., Kitagawa, K., Yoneda, T., Fukui, Y., Fujsawa, M., Bautista, D., & Shirakawa, T. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.21 · Cited by 19

Cellular Immunotherapy of Cancer: An Overview and Future Directions

Tao, Z., Li, S., Ichim, T. E., Yang, J., Riordan, N. H., Yenugonda, V. M., Babić, I., & Kesari, S. (2017) · Immunotherapy · doi:10.2217/imt-2016-0086 · Cited by 19

Cell cycle inhibitors for the treatment of NSCLC

Shcherba, M., Liang, Y., Fernandes, D. L., Perez-Soler, R., & Cheng, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.902935 · Cited by 18

Adenovirus-Based Immunotherapy of Cancer: Promises to Keep

de Gruijl, T. D., & van de Ven, R. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00006-9 · Cited by 18

Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner

Zeng, M., Zhang, W., Li, Y., & Li, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00581-1 · Cited by 17

Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion

Biaoxue, R., Hui, P., Wenlong, G., & Shuanying, Y. (2016) · Scientific Reports · doi:10.1038/srep39355 · Cited by 16

Research progress in the treatment of small cell lung cancer

Qiu, Y., Liu, Z., Yang, W., Zhao, Y., Tang, J., Tang, W., Jin, Y., Fang, L., Zhong, R., & Wang, H. (2016) · Journal of Cancer · doi:10.7150/jca.16822 · Cited by 13

Therapies in the pipeline for small-cell lung cancer: Table 1

Romanidou, O., Imbimbo, M., Mountzios, G., Abidin, A. Z., Morgillo, F., & Califano, R. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw022 · Cited by 13

Immunotherapy Exposes Cancer Stem Cell Resistance and a New Synthetic Lethality

Radvanyi, L. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.160 · Cited by 13

Current Development of Therapeutic Vaccines in Lung Cancer

Banda, J. S. F., Gangane, S., Raza, F., & Massarelli, E. (2025) · Vaccines · doi:10.3390/vaccines13020185 · Cited by 11

In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines

Lőrincz, O., Tóth, J., Molnár, L., Miklós, I., Pántya, K., Megyesi, M., Somogyi, E., Csiszovszki, Z., & Tőke, E. R. (2021) · Cells · doi:10.3390/cells10113048 · Cited by 10

Immunotherapy for small cell lung cancer: the current state and future trajectories

Qiang, M., Liu, H., Yang, L., Wang, H., & Guo, R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01119-5 · Cited by 12

MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy

Janosky, M. D., Sabado, R. L., Cruz, C. M., Vengco, I., Hasan, F., Winer, A., Moy, L. P., & Adams, S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0032-2 · Cited by 9

Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines

Borovjagin, A. V., Gómez-Gutiérrez, J. G., Shirwan, H., & Matthews, Q. L. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1818-4_8 · Cited by 8

Progress in immunotherapy for small cell lung cancer

Zhao, D., Xie, B., Yang, Y., Yan, P., Liang, S., & Lin, Q. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i6.370 · Cited by 8

Prospects and Challenges of Lung Cancer Vaccines

Lin, Z., Chen, Z., Pei, L., Chen, Y., & Ding, Z. (2025) · Vaccines · doi:10.3390/vaccines13080836 · Cited by 7

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?

Guo, H., He, Y., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., & Zhou, C. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1689 · Cited by 6

Novel therapeutic strategies for recurrent SCLC

Moliner, L., Zhang, B., Lamberti, G., Ardizzoni, A., Byers, L. A., & Califano, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104017 · Cited by 7

Neuroendocrine cancer vaccines in clinical trials

Bridle, B. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.68 · Cited by 7

Paclitaxel and carboplatin chemotherapy after platinum‑based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Furubayashi, N., Hori, Y., Morokuma, F., Tomoda, T., Negishi, T., Inoue, T., Kumagai, M., Kuroiwa, K., Tokuda, N., & Nakamura, M. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2253 · Cited by 7

Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine

Yamada, M., Tazawa, H., Suemori, K., Okada, N., Kajiwara, Y., Shoji, R., Nagai, Y., Inoue, H., Hashimoto, N., Kanaya, N., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01219-5 · Cited by 6

Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer

Shanmugam, G., Das, S., Paul, S., Rakshit, S., & Sarkar, K. (2022) · Medical Oncology · doi:10.1007/s12032-022-01841-6 · Cited by 6

Small Cell Lung Cancer: Current and Future Strategies

Lampaki, S., Zarogoulidis, P., Lagoudi, K., Tsavlis, D., Kioumis, I. P., Papakala, E., Lazaridis, G., Huang, H., Hohenforst‐Schmidt, W., Pavlidis, P., et al. (2016) · Oncomedicine · doi:10.7150/oncm.16926 · Cited by 6

Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances

Sanaei, M., Pourbagheri‐Sigaroodi, A., Rezvani, A., Zaboli, E., Salari, S., Masjedi, M. R., & Bashash, D. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122652 · Cited by 6

EGFR nanovaccine in lung cancer treatment

Anggaraditya, P. B., Adiputra, P., & Widiana, I. K. (2019) · Bali Medical Journal · doi:10.15562/bmj.v8i3.1494 · Cited by 4

Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes-Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice

Imhof, D., Pownall, W., Schlange, C., Monney, C., Ortega‐Mora, L. M., Ojo, K. K., A, W. C. V. V., Oevermann, A., & Hemphill, A. F. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.901056 · Cited by 4

Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer

Dondulkar, A., Akojwar, N., Katta, C. B., Khatri, D. K., Mehra, N. K., Singh, S. B., & Madan, J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211104155604 · Cited by 4

Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial

González‐Cao, M., Sisteré‐Oró, M., Morán, T., Reguart, N., Cabezón, R., Hernández, A. A., Román-Lladó, R., Molina‐Vila, M. Á., Birgin, K., Domenjo‐Vila, E., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015351 · Cited by 2

The Possible Protective Role of Echinacea and Ginger and both of them on the Lung of Diabetic Male Rats: Histological and Immunohistochemical Study

Ahmed, G., Abdel-Aziz, H. O., Elsayed, H., & Adly, M. (2021) · The Egyptian Journal of Histology · doi:10.21608/ejh.2021.71195.1457 · Cited by 2

Summary of Presentations from the 11th Targeted Therapies for Lung Cancer Meeting; Immunotherapy and Vaccines for Treatment of Lung Cancer

Ujházy, P., & Carbone, D. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000407570.29900.a5 · Cited by 2

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage

Ding, X., Cao, H., Chen, X., Zhao, Y., Jin, H., Niu, C. S., Ma, K., Liu, Z., Chen, J., Wang, X., et al. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.02.001 · Cited by 2

Initial results of a phase II trial of patients with extensive stage small cell lung cancer (SCLC) immunized with dendritic cells (DC) transduced with wild-type p53

Gabrilovich, D. I., Mirza, N., Chiappori, A., Dunn, M. W., Willis, M., Janssen, W. E., Smilee, R. C., Menander, K., Chada, S., & Antonia, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2543 · Cited by 5

Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT)

Chiappori, A., Sereno, M., Gabrilovich, D. I., Mirza, N. N., Dunn, M. W., Janssen, W. E., Smilee, R. C., Menander, K. B., Chada, S., & Antonia, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3012 · Cited by 5

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64

M17-02: Immunotherapy of extensive stage small cell lung cancer with dendritic cell based p53 vaccine

Antonia, S. J., Mirza, N. N., Chiappori, A., Fricke, I., Bepler, G., Simon, G. R., Janssen, W. E., Lee, J., Menander, K., Chada, S., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000282976.88618.ff